Contacts:Monique Greer +1 206.272.4343 email@example.com Ed Bell+1 206.282.7100 firstname.lastname@example.org SOURCE Cell Therapeutics, Inc.
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Stocks with insider trader activity include LPNT, PATK and CTIC